RxDoctor Payments Data

Aimee Kantzler, NP

Nurse Practitioner · Dearborn Heights, MINPI 1013169846

Payments from drug & device makers

$1,217in general payments, 2019–2025

Across 64 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$251
  • AbbVie$191
  • Lilly USA, LLC$174
  • Teva Pharmaceuticals USA, Inc.$155
  • E.r. Squibb & Sons, L.L.C.$125
  • UCB, Inc.$80
  • plus $240 from 10 others

What the payments were for

  • Food & beverage$1,19598%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,217 in reported general payments places this provider in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$24,574
Medicare patients
213
Services billed
282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$85,417
Nurtec OdtRimegepant Sulfate35$43,740
Lacosamide105$27,695
UbrelvyUbrogepant19$19,625
Dimethyl Fumarate26$17,758
Rufinamide17$17,369
QuliptaAtogepant13$13,973
Aimovig AutoinjectorErenumab-Aooe13$10,702
Levetiracetam131$4,233
Carbamazepine ErCarbamazepine18$3,435
Memantine Hcl125$2,863
Donepezil Hcl191$2,489
Primidone57$2,320
Oxcarbazepine17$2,279
Carbidopa-LevodopaCarbidopa/Levodopa53$1,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$155$85,41714 claims
PfizerNurtec Odt$29$43,74035 claims
AbbVieUbrelvy, Qulipta$191$33,59832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Dearborn Heights

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →